Last reviewed · How we verify

AERAS-402 3 x 10^8 vp

Aeras · Phase 2 active Biologic

AERAS-402 3 x 10^8 vp is a Viral vector vaccine Biologic drug developed by Aeras. It is currently in Phase 2 development for Tuberculosis prevention (boost vaccination in BCG-primed individuals), Tuberculosis prevention in HIV-positive individuals. Also known as: AERAS-402.

AERAS-402 is a replication-deficient adenovirus vector vaccine that expresses Mycobacterium tuberculosis antigens to stimulate immune responses against tuberculosis.

AERAS-402 is a replication-deficient adenovirus vector vaccine that expresses Mycobacterium tuberculosis antigens to stimulate immune responses against tuberculosis. Used for Tuberculosis prevention (boost vaccination in BCG-primed individuals), Tuberculosis prevention in HIV-positive individuals.

At a glance

Generic nameAERAS-402 3 x 10^8 vp
Also known asAERAS-402
SponsorAeras
Drug classViral vector vaccine
TargetMycobacterium tuberculosis antigens (Ag85A, TB10.4)
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhasePhase 2

Mechanism of action

AERAS-402 uses a recombinant adenovirus serotype 35 (Ad35) as a viral vector to deliver TB antigens (Ag85A and TB10.4) intramuscularly, triggering both CD8+ and CD4+ T-cell responses. The vaccine is designed to boost immunity in individuals previously vaccinated with BCG or to provide primary immunization against tuberculosis infection and disease.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about AERAS-402 3 x 10^8 vp

What is AERAS-402 3 x 10^8 vp?

AERAS-402 3 x 10^8 vp is a Viral vector vaccine drug developed by Aeras, indicated for Tuberculosis prevention (boost vaccination in BCG-primed individuals), Tuberculosis prevention in HIV-positive individuals.

How does AERAS-402 3 x 10^8 vp work?

AERAS-402 is a replication-deficient adenovirus vector vaccine that expresses Mycobacterium tuberculosis antigens to stimulate immune responses against tuberculosis.

What is AERAS-402 3 x 10^8 vp used for?

AERAS-402 3 x 10^8 vp is indicated for Tuberculosis prevention (boost vaccination in BCG-primed individuals), Tuberculosis prevention in HIV-positive individuals.

Who makes AERAS-402 3 x 10^8 vp?

AERAS-402 3 x 10^8 vp is developed by Aeras (see full Aeras pipeline at /company/aeras).

Is AERAS-402 3 x 10^8 vp also known as anything else?

AERAS-402 3 x 10^8 vp is also known as AERAS-402.

What drug class is AERAS-402 3 x 10^8 vp in?

AERAS-402 3 x 10^8 vp belongs to the Viral vector vaccine class. See all Viral vector vaccine drugs at /class/viral-vector-vaccine.

What development phase is AERAS-402 3 x 10^8 vp in?

AERAS-402 3 x 10^8 vp is in Phase 2.

What are the side effects of AERAS-402 3 x 10^8 vp?

Common side effects of AERAS-402 3 x 10^8 vp include Injection site pain or erythema, Fever, Myalgia, Fatigue.

What does AERAS-402 3 x 10^8 vp target?

AERAS-402 3 x 10^8 vp targets Mycobacterium tuberculosis antigens (Ag85A, TB10.4) and is a Viral vector vaccine.

Related